Alpha 2.0
Login Register
» Authors » Ulrich Lucking

Ulrich Lucking

Explore the profile of Ulrich Lucking including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 570
Followers 0
Related Specialties
Chemistry
Pharmacology
Biochemistry
Top 10 Co-Authors
Philip Lienau
Gerhard Siemeister
Martina Schafer
Dominik Mumberg
Hans Briem
Franz von Nussbaum
Ulf Bomer
Dieter Moosmayer
Lars Wortmann
Antje M Wengner
Published In
Chemistry
ChemMedChem
J Med Chem
Chembiochem
Angew Chem Int Ed Engl
Affiliations
Soon will be listed here.
Recent Articles
1.
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe
Ali A, Bauser M, Bertrand S, Blackaby W, Boss C, Bossart M, et al.
ChemMedChem . 2023 Jun; 18(13):e202300127. PMID: 37276375
The status of industrial Medicinal Chemistry was discussed with European Medicinal Chemistry Leaders from large to mid-sized pharma and CRO companies as well as biotechs. The chemical modality space has...
2.
New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective
Lucking U
Chemistry . 2022 Jul; 28(56):e202201993. PMID: 35789054
Extension of the medicinal chemistry toolbox is in the vital interest of drug designers. However, the diffusion of an innovation can be a lengthy process. Along these lines, it took...
3.
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Berger M, Wortmann L, Buchgraber P, Lucking U, Zitzmann-Kolbe S, Wengner A, et al.
J Med Chem . 2021 Aug; 64(17):12723-12737. PMID: 34428039
Eukaryotes have evolved two major pathways to repair potentially lethal DNA double-strand breaks. Homologous recombination represents a precise, DNA-template-based mechanism available during the S and G2 cell cycle phase, whereas...
4.
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Lucking U, Kosemund D, Bohnke N, Lienau P, Siemeister G, Denner K, et al.
J Med Chem . 2021 Jul; 64(15):11651-11674. PMID: 34264057
Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development,...
5.
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Wells C, Al-Ali H, Andrews D, Asquith C, Axtman A, Dikic I, et al.
Int J Mol Sci . 2021 Jan; 22(2). PMID: 33429995
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show...
6.
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Lucking U, Wortmann L, Wengner A, Lefranc J, Lienau P, Briem H, et al.
J Med Chem . 2020 Jun; 63(13):7293-7325. PMID: 32502336
The ATR kinase plays a key role in the DNA damage response by activating essential signaling pathways of DNA damage repair, especially in response to replication stress. Because DNA damage...
7.
Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur-Fluorine Exchange (SuFEx) Reaction
Greed S, Briggs E, Idiris F, White A, Lucking U, Bull J
Chemistry . 2020 May; 26(55):12533-12538. PMID: 32428384
Sulfonimidamides present exciting opportunities as chiral isosteres of sulfonamides, with potential for additional directional interactions. Here, we present the first modular enantioselective synthesis of sulfonimidamides, including the first stereoselective synthesis...
8.
Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties
Boulard E, Zibulski V, Oertel L, Lienau P, Schafer M, Ganzer U, et al.
Chemistry . 2020 Jan; 26(19):4378-4388. PMID: 31961028
A short synthetic approach with broad scope to access five- to seven-membered cyclic sulfoximines in only two to three steps from readily available thiophenols is reported. Thus, simple building blocks...
9.
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo
Wortmann L, Lindenthal B, Muhn P, Walter A, Nubbemeyer R, Heldmann D, et al.
J Med Chem . 2019 Nov; 62(22):10321-10341. PMID: 31670515
The human luteinizing hormone receptor (hLH-R) is a member of the glycoprotein hormone family of G-protein-coupled receptors (GPCRs), activated by luteinizing hormone (hLH) and essentially involved in the regulation of...
10.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
Wengner A, Siemeister G, Lucking U, Lefranc J, Wortmann L, Lienau P, et al.
Mol Cancer Ther . 2019 Oct; 19(1):26-38. PMID: 31582533
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on alternative repair pathways. The ataxia...